Do you want to read an article? Please log in or register.
Assessment of a Polygenic Risk Score in Screening for Prostate Cancer
Genitourinary Cancer
Related content
Genitourinary Cancer
A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer
Cancer Epidemiol Biomarkers Prev
Farazi M, Yang X, Gehl CJ, Barnett GC, Burnet NG, Chang-Claude J, Parker CC, Dunning AM, Azria D, Choudhury A, Rancati T, De Ruysscher D, Seibold P, Sperk E, Talbot CJ, Veldeman L, Webb AJ, Elliott R, Aguado-Barrera ME, Carballo AM, Fuentes-Ríos O, Gómez-Caamaño A, Peleteiro P, Vega A, Ostrer H, Rosenstein BS, Saito S, Parliament M, Usmani N, Marples B, Chen Y, Morrow G, Messing E, Janelsins MC, Hall W, West CML, Auer PL, Kerns S
doi: 10.1158/1055-9965.EPI-24-1228
Genitourinary Cancer
Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance
JAMA Oncol
Goss LB, Liu M, Zheng Y, Guo B, Conti DV, Haiman CA, Kachuri L, Catalona WJ, Witte JS, Lin DW, Newcomb LF, Darst BF
doi: 10.1001/jamaoncol.2024.5398
Genitourinary Cancer
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring System
Prostate
Takahashi T, Nakashima M, Maruno K, Hazama T, Yamada Y, Kikkawa K, Umeoka S, Tamaki M, Ito N
doi: 10.1002/pros.24821
Genitourinary Cancer
Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Prostate
Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O
doi: 10.1002/pros.24855
Genitourinary Cancer
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study
Prostate Cancer Prostatic Dis
Deivasigamani S, Adams ES, Stock S, Kotamarti S, Séguier D, Taha T, Howard LE, Aminsharifi A, Jibara G, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Guerrios-Rivera L, Freedland SJ, Polascik TJ
doi: 10.1038/s41391-024-00880-6
Genitourinary Cancer
Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis
Prostate
Bahri RA, Mohammadi A, Yar EZ, Rezayat M, Heshmat R, Aghamir SMK
doi: 10.1002/pros.24851
Genitourinary Cancer
Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort
Cancer Epidemiol Biomarkers Prev
Liss MA, Zeltser N, Zheng Y, Lopez C, Liu M, Patel Y, Yamaguchi TN, Eng SE, Tian M, Semmes OJ, Lin DW, Brooks JD, Wei JT, Klein EA, Tewari AK, Mosquera JM, Khani F, Robinson BD, Asad M, Troyer DA, Kagan J, Sanda MG, Thompson IM, Boutros PC, Leach RJ
doi: 10.1158/1055-9965.EPI-24-0326
COMMENTED
Genitourinary Cancer
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV
doi: 10.1001/jamaoncol.2025.0110
Genitourinary Cancer
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer
Prostate Cancer Prostatic Dis
Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D
doi: 10.1038/s41391-024-00930-z